MedPath

Ganciclovir

Generic Name
Ganciclovir
Brand Names
Cytovene, Zirgan
Drug Type
Small Molecule
Chemical Formula
C9H13N5O4
CAS Number
82410-32-0
Unique Ingredient Identifier
P9G3CKZ4P5
Background

An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication

For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions
CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis
Clinical Trials
Related News

(Val)Ganciclovir TDM in Transplant Recipients

Conditions
Cytomegalovirus Infections
Interventions
First Posted Date
2018-10-09
Last Posted Date
2019-10-10
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
100
Registration Number
NCT03698435
Locations
🇳🇱

UMCG, Groningen, Netherlands

Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.

Phase 3
Completed
Conditions
Transplantation Infection
Cytomegalovirus Infections
Interventions
First Posted Date
2018-10-09
Last Posted Date
2023-09-15
Lead Sponsor
Maimónides Biomedical Research Institute of Córdoba
Target Recruit Count
150
Registration Number
NCT03699254
Locations
🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

🇪🇸

Hospital Univesitario Reina Sofía, Córdoba, Spain

🇪🇸

Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

and more 4 locations

High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients

Not Applicable
Completed
Conditions
Infection Viral
Uveitis, Posterior
Interventions
First Posted Date
2018-07-26
Last Posted Date
2018-07-26
Lead Sponsor
Aier School of Ophthalmology, Central South University
Target Recruit Count
33
Registration Number
NCT03598452

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

Phase 2
Completed
Conditions
Cytomegalovirus Anterior Uveitis
Interventions
Drug: Placebo Oral Tablet
Drug: Topical placebo
First Posted Date
2018-07-13
Last Posted Date
2024-12-06
Lead Sponsor
University of California, San Francisco
Target Recruit Count
51
Registration Number
NCT03586284
Locations
🇺🇸

Proctor Foundation, UCSF, San Francisco, California, United States

🇹🇭

Chulalongkorn University, Bangkok, Thailand

🇹🇭

Chiang Mai University, Chiang Mai, Thailand

and more 1 locations

Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex Keratitis

Not Applicable
Conditions
Herpes Simplex Keratitis
Interventions
Procedure: FLDEB
Device: Femtosecond laser
First Posted Date
2017-07-14
Last Posted Date
2018-02-22
Lead Sponsor
Chunxiao Wang
Target Recruit Count
100
Registration Number
NCT03217474
Locations
🇨🇳

Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity, Guangzhou, Guangdong, China

CMV-CTL for the Treatment of CMV Infection After HSCT

Phase 4
Completed
Conditions
Cytomegalovirus Infections
Hematological Disease
Interventions
Biological: donor derived cytomegalovirus specific T lymphocytes
First Posted Date
2016-12-28
Last Posted Date
2023-04-25
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
5
Registration Number
NCT03004261
Locations
🇨🇳

Shanghai Jiao Tong University Affilated Shanghai General Hospital, Shanghai, Shanghai, China

The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population

Conditions
Renal Transplant Recipients
Interventions
First Posted Date
2016-11-25
Last Posted Date
2016-12-02
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
450
Registration Number
NCT02973464
Locations
🇨🇳

the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis

Phase 4
Completed
Conditions
Cytomegalovirus Infections
Interventions
First Posted Date
2016-10-24
Last Posted Date
2025-05-18
Lead Sponsor
Singapore National Eye Centre
Target Recruit Count
25
Registration Number
NCT02943057
Locations
🇸🇬

Singapore National Eye Centre, Singapore, Singapore

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Phase 3
Completed
Conditions
Cytomegalovirus (CMV)
Interventions
First Posted Date
2016-10-13
Last Posted Date
2021-11-03
Lead Sponsor
Shire
Target Recruit Count
352
Registration Number
NCT02931539
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 129 locations

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

Phase 2
Terminated
Conditions
Herpes Zoster Keratitis
Interventions
First Posted Date
2015-03-06
Last Posted Date
2021-07-08
Lead Sponsor
Northwestern University
Target Recruit Count
8
Registration Number
NCT02382588
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy